ClinicalTrials.gg
CompletedNCT04197817Updated Dec 13, 2019

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

A Phase 1 interventional study of JS002 and Placebo in Hypercholesterolemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-13.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Dec 2017, registered Dec 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Hypercholesterolemia with a site in China — 11 open to participants now, 18 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
36th of 54
84 · median 206
Started
2017
with 1 other
Phase 1
12 of 60
2 open now
Registered
24th of 60
by date

Among the 60 studies in Hypercholesterolemia with a site in China, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2017, is one of 12 in phase 1, and was the 24th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

11 of the 60 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of JS002 in healthy subjects.

In this study, the dose ascending design includes five dose level cohorts (15 mg, 50 mg, 150 mg, 300 mg, and 450 mg) administered by subcutaneous injection, and three intravenous administration cohorts (15 mg, 150 mg, and 450 mg). Each cohort will enroll 8 to 12 subjects (distribution of study drug and placebo in a 3:1 ratio).

The duration of the study is 84-day per subjects.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men or women aged 18 to 45 years old at screening visit;
  2. Have the ability to read and understand, volunteer to participate in the study, and signed written .
  3. The (BMI) at screening visit was in the range of 18 to 30 kg/m2 (inclusive) and the body weight ≥ 50 kg.
  4. The sitting blood pressure ≥90/60 mmHg and \<140/90 mmHg at screening visit.
  5. Serum LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and \< 190 mg/dL (4.9 mmol/L) at screening visit.
  6. Serum Triglyceride (TG) level \< 250 mg/dL (2.8 mmol/L) at screening visit.
  7. No fertility [female: documented hysterectomy, bilateral oophorectomy, tubal ligation or other female permanent sterilization, or menopause (menopause for more than one year)], or those with fertility are willing to take, during the entire study period, strict and effective measures, in addition, female subjects with fertility should have a negative blood/urine pregnancy test at screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who meet any of the following criteria will be excluded from the study:
  2. Evolocumab and/or Alirocumab, or other targeted drugs to PCSK9, has been used at any time.
  3. Any therapeutic or research biological agents has been used during the first 6 months of baseline/random (Day 0).
  4. Participated in any clinical study within 3 months prior to baseline/random (Day 0).
  5. Any drug or health supplement that affects blood lipids or lipid metabolism during the first 30 days of baseline/random (Day 0), including but not limited to: Probucol, statins (e.g. Atorvastatin, Rosuvastatin, etc.), cholesterol absorption inhibitors (such as Ezetimibe), bile acid sequestrants (such as Cholestyramine), red yeast and hawthorn preparations, fibrates, high-purity fish oil preparations (or omega-fatty acids ≥ 1000 mg / day) and niacin preparation (nicotinic acid ≥ 50 mg), etc.
  6. Start a new intense exercise or diet control within 30 days of random (Day 0) or major changes to previous diet and lifestyle (including exercise, smoking and drinking). The following conditions occur before the baseline/random (Day 0) 1 day (ie Day-1) need to be excluded:

    • Creatine kinase (CK) ≥ 3 times the (ULN) (Note: related to exercise), or
    • Urinary cotinine is positive, or
    • Positive alcohol saliva test.
  7. Previous or concomitant diseases (such as nephrotic syndrome, liver disease, diabetes, hypothyroidism, etc.) or any abnormalities found in physical examinations, laboratory tests, and , which would make the subject unsuitable for this study.
  8. The medical history or clinical evidence indicates that the subject had severe acute or chronic disease (including not limited to: heart, kidney, nerves, endocrine, blood, immunity, infection, metabolic disorders, etc.), and the disease has not been controlled, which may confuse the outcome of the study or put the subject at risk judged by the investigator, The following situations need to be excluded:

    • had major surgery in the last 6 months, or
    • has been hospitalized (e.g. infection) in the last 3 months, or
    • donated blood or blood loss ≥500 mL in the past 3 months, or
    • has used any prescription or over-the-counter drugs in the past 1 month.
  9. Transplantation History of organs (such as heart, lung, liver, kidney, etc.) Malignant tumors history, except for cervical carcinoma in situ or surgically resected skin cancer (basal cells and squamous epithelial cells) for more than 5 years.
  10. Drug abuse or alcohol dependence in the past 1 year.
  11. infection, or HIV antibody positive at screening visit.
  12. Syphilis infection, or serotonin antibody (TPPA) positive at screening visit.
  13. surface antigen (HBsAg) was positive at screening visit.
  14. virus (HCV) antibody was positive at screening visit.
  15. (AST) and alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN); alkaline phosphatase and ≥ 1.5 times the upper limit of normal (ULN).
  16. Allergy history to mammalian-derived biological agents, including monoclonal antibodies.
  17. Women during pregnancy and lactation.
  18. Any other investigator believes that the subject is not suitable for the study, such as the subject has potential compliance issues, cannot complete all tests and assessments according to the protocol requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    JS002

    JS002, Subcutaneous or intravenous injection

    Drug: JS002

  • Placebo comparator
    Placebo,

    Placebo,Subcutaneous or intravenous injection

    Drug: Placebo

Interventions

  • DrugOngericimabStudies of OngericimabOngericimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design

    Also known as: Recombinant humanized Anti- PCSK9 monoclonal antibody

  • DrugPlacebo

    Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design

    Also known as: Placebo of Recombinant humanized Anti- PCSK9 monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events(SAE, drug-related (S)AE etc)based on physical examinations, vital signs, 12 lead ECGs , laboratory tests and injection site reactions.

    Time frame: Up to 84 days after dose administration

Secondary outcomes

  1. Number of participants with anti-drug antibodies.

    Time frame: Up to 84 days after dose administration

  2. Serum concentrations of JS002 at different timepoint after the drug administration.

    Time frame: Up to 84 days after dose administration

  3. Change from baseline in LDL-C and other lipid parameters (TC, HDL-C, non-HDL-C, VLDL-C, ApoB, ApoA1, Lp(a) and TG).

    Time frame: Up to 84 days after dose administration

Other outcomes

  1. Changes over time of serum concentrations of JS002.

    Time frame: Up to 84 days after dose administration

  2. Changes over time of LDL-C.

    Time frame: Up to 84 days after dose administration

  3. Change over time of unbound/total serum PCSK9.

    Time frame: Up to 84 days after dose administration

07

Study locations

1 site
  • Fuwai Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Aug 2018, 8 months.

Of 46 phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2019
First posted
Dec 13, 2019
StartActual
Dec 11, 2017
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 14, 2018
Last update
Dec 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04197817
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Dec 11, 2017
Primary completion
Aug 14, 2018
Completion
Aug 14, 2018
Last update
Dec 13, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion